<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01100359</url>
  </required_header>
  <id_info>
    <org_study_id>MUI-AGO-15</org_study_id>
    <secondary_id>CDR0000669712</secondary_id>
    <secondary_id>EUDRACT-2007-004060-40</secondary_id>
    <secondary_id>EU-21027</secondary_id>
    <nct_id>NCT01100359</nct_id>
  </id_info>
  <brief_title>Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer</brief_title>
  <official_title>Phase II Multicenter Trial of the Austrian AGO With the Combination of Liposomal Doxorubicin (Myocet®) and Carboplatin in Primary Advanced or Metastatic and Recurrent Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as liposome-encapsulated doxorubicin citrate and&#xD;
      carboplatin, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well liposome-encapsulated doxorubicin citrate&#xD;
      given together with carboplatin works in treating patients with advanced or metastatic&#xD;
      recurrent endometrial cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess activity of the combination of liposome-encapsulated doxorubicin citrate and&#xD;
           carboplatin in patients with primary advanced or metastatic recurrent carcinoma of the&#xD;
           endometrium.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess the toxicity and feasibility of this regimen in these patients.&#xD;
&#xD;
        -  To determine the progression-free survival and overall survival of these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive liposome-encapsulated doxorubicin citrate IV over 1 hour followed by&#xD;
      carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6-9 courses in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Tissue array and immunohistochemistry analysis are conducted on paraffin-embedded tumor&#xD;
      blocks of the primarily operated tissue of all patients for different markers (e.g.,&#xD;
      progesterone-/estrogen receptor, HER2-receptor, soluble L1-molecule, Topo 2a) to examine&#xD;
      tumor characteristics.&#xD;
&#xD;
      Quality of life is assessed at baseline, during study treatment, at completion of study&#xD;
      treatment, and then at 1 year after completion of study treatment.&#xD;
&#xD;
      After completion of study therapy, patients are followed up every 3 months for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <primary_completion_date type="Anticipated">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Endometrial Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposome-encapsulated doxorubicin citrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of endometrial carcinoma, including any of the following cellular types:&#xD;
&#xD;
               -  Mixed Mullerian carcinoma&#xD;
&#xD;
               -  Serous carcinoma&#xD;
&#xD;
               -  Clear cell carcinoma&#xD;
&#xD;
          -  Primary advanced (FIGO stage III or stage IV) or metastatic recurrent disease&#xD;
&#xD;
          -  Disease not curable by surgery&#xD;
&#xD;
          -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm with&#xD;
             x-ray, physical exam, or non-spiral CT scan OR ≥ 10 mm with spiral CT scan or MRI&#xD;
&#xD;
          -  No known cerebral metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Creatinine ≤ 1.25 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.25 times ULN&#xD;
&#xD;
          -  AST/ALT &lt; 3 times ULN&#xD;
&#xD;
          -  Glomerular filtration rate ≥ 50 mL/min&#xD;
&#xD;
          -  LVEF ≥ 50% by ECHO&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No NYHA class II-IV congestive heart failure&#xD;
&#xD;
          -  No third degree or complete heart block unless a pacemaker is in place&#xD;
&#xD;
          -  No other malignancy within the past 5 years&#xD;
&#xD;
          -  No concomitant medical illness (e.g., uncontrolled infection, uncontrolled angina, or&#xD;
             other relevant illness) that makes the prescribed treatments within this study&#xD;
             unfeasible&#xD;
&#xD;
          -  No known hypersensitivity to study drugs&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy for disease recurrence&#xD;
&#xD;
          -  At least 12 months since prior adjuvant therapy containing anthracyclines with&#xD;
             cumulative doses not exceeding the following:&#xD;
&#xD;
               -  Epirubicin 600 mg/m²&#xD;
&#xD;
               -  Doxorubicin 300 mg/m²&#xD;
&#xD;
          -  At least 6 months since prior adjuvant therapy containing platinum&#xD;
&#xD;
          -  At least 4 weeks since completion of radiotherapy involving the whole pelvis&#xD;
&#xD;
          -  No concurrent radiotherapy or planned radiotherapy after study&#xD;
&#xD;
          -  No concurrent endocrine, immunological, or other anticancer therapy&#xD;
&#xD;
          -  No concurrent participation in another investigational drug study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Marth, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University Innsbruck</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Innsbruck Universitaetsklinik</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>43-512-504-23050</phone>
      <email>Christian.marth@i-med.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>April 7, 2010</study_first_submitted>
  <study_first_submitted_qc>April 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2010</study_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <keyword>endometrial clear cell carcinoma</keyword>
  <keyword>recurrent endometrial carcinoma</keyword>
  <keyword>stage IIIA endometrial carcinoma</keyword>
  <keyword>stage IIIB endometrial carcinoma</keyword>
  <keyword>stage IIIC endometrial carcinoma</keyword>
  <keyword>stage IVA endometrial carcinoma</keyword>
  <keyword>stage IVB endometrial carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

